• HOME
• ABOUT
  • MANAGEMENT
  • BOARD OF DIRECTORS
  • SCIENTIFIC AND MEDICAL ADVISORY BOARD
  • ACADEMIC COLLABORATIONS
  • PARTNERSHIPS
• SCIENCE
  • TARGET
  • METABOLIC SYNDROME
  • TYPE 2 DIABETES
  • INSULIN SENSITIZERS
  • NEURODEGENERATION
• PIPELINE
  • MSDC-0160
  • MSDC-0602
  • MARKET
• NEWSROOM
  • NEWS RELEASES
  • IN THE NEWS
  • PUBLICATIONS
  • PRESENTATIONS
  • FACT SHEET
• CONTACT
  • LOCATION
  • CAREERS
  • MEDIA CONTACT

Colca JR, Kletzien RF
Expert Opin Investig Drugs. 2006 Mar;15(3):205-10.
What has prevented the expansion of insulin sensitisers?
 
Colca JR.
Biochem Pharmacol.  2006 Jul 14;72(2):125-31. Epub 2006 Feb 10.
Insulin sensitizers may prevent metabolic inflammation.
 
Bolten CW , Blanner PM , McDonald WG , Staten NR , Mazzarella RA, Arhancet GB , Meier MF, Weiss DJ, Sullivan PM, Hromockyj AE , Kletzien RF, Colca JR.
Gene Regul Syst Bio. 2007 Sep 17;1:73-82.
Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.

Colca JR, Kletzien RF
Adv Pharmacol. 2009;57:237-51. Epub 2009 Nov 27.
Current and emerging strategies for treating dyslipidemia and macrovascular disease.